Delhi Daily News | FDA rejects Novartis heart failure drug serelaxin PharmaTimes The US Food and Drug Administration has issued a complete response letter regarding the Biologics License Application for serelaxin for the treatment of acute heart failure, stating that further evidence on its efficacy is required. The rejection comes ... US regulator rejects Novartis heart failure drug FDA Rejects Novel Novartis Drug For Acute Heart Failure |
